Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441YAN ZHAO; THOMAS, Huw D; BATEY, Michael A et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5354-5362, issn 0008-5472, 9 p.Article

Preclinical restenosis models : Challenges and successesTOUCHARD, Arturo G; SCHWARTZ, Robert S.Toxicologic pathology. 2006, Vol 34, Num 1, pp 11-18, issn 0192-6233, 8 p.Conference Paper

Preclinical predictors of clinical safety : Opportunities for improvementSISTARE, F. D; DEGEORGE, J. J.Clinical pharmacology and therapeutics. 2007, Vol 82, Num 2, pp 210-214, issn 0009-9236, 5 p.Article

Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established TumorsJUAN FU; MALM, Ian-James; KADAYAKKARA, Deepak K et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 15, pp 4042-4052, issn 0008-5472, 11 p.Article

Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor TherapyVAN LINT, Sandra; GOYVAERTS, Cleo; THIELEMANS, Kris et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 7, pp 1661-1671, issn 0008-5472, 11 p.Article

Preclinical assessment of cardiac toxicityKETTENHOFEN, Ralf; BOHLEN, Heribert.Drug discovery today. 2008, Vol 13, Num 15-16, pp 702-707, issn 1359-6446, 6 p.Article

Application of genomics in preclinical drug safety evaluationLORD, Peter G; NIE, Alex; MCMILLIAN, Michael et al.Basic & clinical pharmacology & toxicology (Print). 2006, Vol 98, Num 6, pp 537-546, issn 1742-7835, 10 p.Article

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolSHAPIRO, Geoffrey I.Clinical cancer research. 2004, Vol 10, Num 12, pp 4270s-4275s, issn 1078-0432, 2Conference Paper

Outsourcing outlook: Sales figures, project schedules remain strong across the industryMILLER, Jim.Pharmaceutical technology. 2002, Vol 26, Num 10, pp 156-160, issn 0147-8087, 3 p.Article

Preclinical testing strategiesOLEJNICZAK, Klaus; GUNZEL, Peter; BASS, Rolf et al.Drug information journal. 2001, Vol 35, Num 2, pp 321-336, issn 0092-8615Article

Preclinical safety evaluation of human gene therapy productsVERDIER, F; DESCOTES, J.Toxicological sciences (Print). 1999, Vol 47, Num 1, pp 9-15, issn 1096-6080Article

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK InhibitorWONG, Harvey; VERNILLET, Laurent; HOEFLICH, Klaus P et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3090-3099, issn 1078-0432, 10 p.Article

China's unique position in discovery and preclinical researchBOUTELLIER, Roman; ULLMAN, Fredrik.Drug discovery today. 2007, Vol 12, Num 1-2, pp 4-7, issn 1359-6446, 4 p.Article

Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in MelanomaABBAS, Sabiha; BHOUMIK, Anindita; DAHL, Russell et al.Clinical cancer research. 2007, Vol 13, Num 22, pp 6769-6778, issn 1078-0432, 10 p., 1Article

2-D tomography of biotissues images in pre-clinic diagnostics of their pre-cancer statesANGELSKY, O. V; TOMKA, Yu. Ya; USHENKO, A. G et al.SPIE proceedings series. 2005, pp 59720N.1-59720N.5, isbn 0-8194-5991-7, 1VolConference Paper

Preclinical characterisation of ¹¹¹In-DTPA-trastuzumabLUB-DE HOOGE, Marjolijn N; KOSTERINK, Jos G. W; PERIK, Patrick J et al.British journal of pharmacology. 2004, Vol 143, Num 1, pp 99-106, issn 0007-1188, 8 p.Article

A postgraduate course in preclinical drug evaluationATKINSON, Jeffrey.Thérapie (Paris). 2004, Vol 59, Num 1, pp 61-62, issn 0040-5957, 2 p.Conference Paper

Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapyALOJ, L; MORELLI, G.Current pharmaceutical design. 2004, Vol 10, Num 24, pp 3009-3031, issn 1381-6128, 23 p.Article

Outsourcing outlook: Gene logic looks to integrate genomics into preclinical testingMILLER, Jim.Pharmaceutical technology (2003). 2003, Vol 27, Num 6, pp 74-76, issn 1543-2521, 2 p.Article

How valid are claims for synergy in published clinical studies?OCANA, A; AMIR, E; YEUNG, C et al.Annals of oncology. 2012, Vol 23, Num 8, pp 2161-2166, issn 0923-7534, 6 p.Article

Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to HumansTEITELBAUM, Zvi; LAVE, Thierry; FREIJER, Jan et al.Clinical pharmacokinetics. 2010, Vol 49, Num 9, pp 619-632, issn 0312-5963, 14 p.Article

Construction and Preclinical Characterization of Fc-mGITRL for the Immunotherapy of CancerPEISHENG HU; ARIAS, Robyn S; SADUN, Rebecca E et al.Clinical cancer research. 2008, Vol 14, Num 2, pp 579-588, issn 1078-0432, 10 p.Article

Preclinical Pharmacokinetics of a HepDirect Prodrug of a Novel Phosphonate-Containing Thyroid Hormone Receptor AgonistFUJITAKI, James M; CABLE, Edward E; ERION, Mark D et al.Drug metabolism and disposition. 2008, Vol 36, Num 11, pp 2393-2403, issn 0090-9556, 11 p.Article

Two-year preclinical testing of perfluoropolyether polymer as a corneal inlayRUO ZHONG XIE; EVANS, Margaret D. M; BOJARSKI, Barbara et al.Investigative ophthalmology & visual science. 2006, Vol 47, Num 2, pp 574-581, issn 0146-0404, 8 p.Article

Preclinical Models Used for Immunogenicity Prediction of Therapeutic ProteinsBRINKS, Vera; WEINBUCH, Daniel; BAKER, Matthew et al.Pharmaceutical research. 2013, Vol 30, Num 7, pp 1719-1728, issn 0724-8741, 10 p.Article